Aligos Therapeutics vs Eloxx Pharmaceuticals
ALGS and ELOX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALGS and ELOX compare
Eloxx Pharmaceuticals is the larger company, worth 2.0 times as much as Aligos Therapeutics ($53.1M against $26.2M).
Aligos Therapeutics grew revenue faster over the last twelve months (122% versus −100% for Eloxx Pharmaceuticals).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALGS | ELOX |
|---|---|---|
| Size and price | ||
| Market cap | $26.2M | $53.1M |
| Share price | $2.10 | $13.15 |
| Change, 1 year | −67.5% | 1195350% |
| Change, 5 years | −99.5% | −97.8% |
| Beta (5Y) | 1.48 | – |
| Employees | 82 | 7 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 1 | 1 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.5× | – |
| P/B | 2.3× | 1.1× (better) |
| Fair value | $2.34 | – |
| Margin of safety | 10.2% | – |
| Growth | ||
| Revenue growth (TTM) | 122% (better) | −100% |
| Profitability | ||
| Operating margin | −1244% | – |
| Net margin | −1137% | – |
| Return on equity | −159% | −54.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.77 | 3.74 (better) |
| Altman Z-score | −24.56 | −4.40 (better) |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 18.4% | 71.8% |
| Held by insiders | – | 42.6% |
| Superinvestors holding | 1 | – |
| Short interest, % of float | – | 2.3% |
Go deeper
- ALGS stock overview
- ALGS income statement
- ALGS valuation and score
- ELOX stock overview
- ELOX income statement
- ELOX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.